Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 29451-29460 Newer>

The Motley Fool April 2, 2008 Dave Mock	Can Instinct Save Sprint Nextel? Can a new touchscreen Samsung phone called Instinct can help Sprint Nextel pull out of its funk and stem the flow of customers to competitors AT&T and Verizon Wireless?
The Motley Fool April 2, 2008 Tim Beyers	Stock Madness Final 4: Apple Who's going to take home the Stock Madness trophy? The latest competition is Apple vs. Starbucks.
The Motley Fool April 2, 2008 Anders Bylund	Stock Madness Final 4: Google Who's going to take home the Stock Madness trophy? The latest competition is Google vs. Canadian National Railway.
The Motley Fool April 2, 2008 Rick Aristotle Munarriz	Turning lululemon Into Lemonade Upscale fitness apparel retailer lululemon athletica is at peace with investors after coming through with better than expected fiscal-fourth-quarter results.
The Motley Fool April 2, 2008 Brian Lawler	Medicines Company Sets Itself Apart Drugmaker Medicines Company wants to distance its angioplasty treatment from heparin.
The Motley Fool April 2, 2008 Brian Lawler	Alexza Establishes a Cash Pipeline Alexza Pharmaceuticals announces that it has signed a deal that will provide it with up to $50 million over the next two years. Investors take note.
The Motley Fool April 2, 2008 Selena Maranjian	World Pop Quiz! Are You a Global Ignoramus? A portion of your portfolio should be invested in international stocks, partly for diversification, and partly because there are plenty of economies in the world that are growing much more briskly than our own.
The Motley Fool April 2, 2008 Rick Aristotle Munarriz	Google's Going to Do What?! Various sources are predicting that Google is about to hook up with eBay's Skype, or that they may buy Expedia.com. Investors, take note; so far these are all just rumors.
The Motley Fool April 2, 2008 Brian Lawler	Bad Timing for AstraZeneca's Good Data AstraZeneca quietly reports a successful clinical study for its cholesterol-lowering lead drug.
The Motley Fool April 2, 2008 Brian Lawler	Following the Drugmaker Formerly Known as Neurochem Neurochem would have been set to hear FDA news on its lead drug candidate Kiacta today, if they had not pulled their marketing application earlier this month.
<Older 29451-29460 Newer> Return to current articles.